Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Melanoma 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1

Interventions

Radiotherapy, Intensity-Modulated 1Immune Checkpoint Inhibitors 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Cancinoma (NPC) × Immune Checkpoint Inhibitors × Head & Neck × Clear all
NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
516 enrolled
Head & Neck

Nasopharyngeal Cancinoma (NPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡